Published in Bioconjug Chem on June 15, 2011
Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc Natl Acad Sci U S A (2013) 1.20
Materials innovation for co-delivery of diverse therapeutic cargos. RSC Adv (2013) 0.84
Toll-like receptors and innate immunity. Nat Rev Immunol (2001) 16.50
CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol (2001) 9.19
TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol (2004) 8.06
T cell anergy. Annu Rev Immunol (2001) 7.15
Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat Immunol (2005) 4.30
Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nat Immunol (2007) 4.09
The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature (2008) 3.93
Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9. Nat Immunol (2008) 3.61
The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation. Immunity (2008) 3.50
The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol (2007) 3.44
New horizons in adjuvants for vaccine development. Trends Immunol (2008) 2.85
Innate immune recognition of, and regulation by, DNA. Trends Immunol (2006) 2.57
pH-dependent perforation of macrophage phagosomes by listeriolysin O from Listeria monocytogenes. J Exp Med (1997) 2.26
Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim Biophys Acta (2001) 1.78
Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat Biotechnol (2000) 1.76
Endocytosis and intracellular fate of liposomes using pyranine as a probe. Biochemistry (1990) 1.60
TLR9 as a key receptor for the recognition of DNA. Adv Drug Deliv Rev (2008) 1.52
Delivery of macromolecules into cytosol using liposomes containing hemolysin from Listeria monocytogenes. J Biol Chem (1996) 1.49
Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol (2001) 1.33
Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur J Immunol (2000) 1.24
Listeriolysin O-liposome-mediated cytosolic delivery of macromolecule antigen in vivo: enhancement of antigen-specific cytotoxic T lymphocyte frequency, activity, and tumor protection. Biochim Biophys Acta (2002) 1.16
Recognition of liposomes by cells: in vitro binding and endocytosis mediated by specific lipid headgroups and surface charge density. Biochim Biophys Acta (1992) 1.14
Conjugation of ligands at the 5'-end of CpG DNA affects immunostimulatory activity. Bioconjug Chem (2002) 1.11
Incorporation of CpG oligonucleotide ligand into protein-loaded particle vaccines promotes antigen-specific CD8 T-cell immunity. Bioconjug Chem (2007) 1.09
Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells. J Immunol (2001) 1.09
Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN. Cancer Immunol Immunother (2007) 1.08
Organization of red cell glycolytic enzymes; cell coat phosphorus transfer. Ann N Y Acad Sci (1958) 1.06
Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides. Pharm Res (2007) 1.04
Novel approaches to vaccine delivery. Pharm Res (2004) 1.03
In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines. Mol Pharm (2009) 1.02
The cell biology of Listeria monocytogenes infection (escape from a vacuole). Ann N Y Acad Sci (1994) 1.02
Curvature and composition-dependent lipid asymmetry in phosphatidylcholine vesicles containing phosphatidylethanolamine and gangliosides. Biochim Biophys Acta (1989) 1.02
Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine (1995) 1.00
Differential cytosolic delivery and presentation of antigen by listeriolysin O-liposomes to macrophages and dendritic cells. Mol Pharm (2005) 0.94
Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine (2003) 0.91
Cytosolic delivery of viral nucleoprotein by listeriolysin O-liposome induces enhanced specific cytotoxic T lymphocyte response and protective immunity. Mol Pharm (2004) 0.86
Enhanced in vivo gene expression mediated by listeriolysin O incorporated anionic LPDII: Its utility in cytotoxic T lymphocyte-inducing DNA vaccine. J Control Release (2010) 0.86
Innate recognition of bacteria by a macrophage cytosolic surveillance pathway. Proc Natl Acad Sci U S A (2002) 3.85
Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev (2003) 3.25
Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J Exp Med (2006) 2.57
A specific gene expression program triggered by Gram-positive bacteria in the cytosol. Proc Natl Acad Sci U S A (2004) 2.10
Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity (2011) 1.70
Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res (2002) 1.37
Accelerated macrophage apoptosis induces autoantibody formation and organ damage in systemic lupus erythematosus. J Immunol (2006) 1.28
Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase. J Biol Chem (2003) 1.19
Listeriolysin O-liposome-mediated cytosolic delivery of macromolecule antigen in vivo: enhancement of antigen-specific cytotoxic T lymphocyte frequency, activity, and tumor protection. Biochim Biophys Acta (2002) 1.16
Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase. J Biol Chem (2008) 1.04
Enhanced gene delivery using disulfide-crosslinked low molecular weight polyethylenimine with listeriolysin o-polyethylenimine disulfide conjugate. J Control Release (2008) 0.97
Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach. Mol Pharm (2011) 0.96
Differential cytosolic delivery and presentation of antigen by listeriolysin O-liposomes to macrophages and dendritic cells. Mol Pharm (2005) 0.94
Localization of protein kinase C epsilon to macrophage vacuoles perforated by Listeria monocytogenes cytolysin. Cell Microbiol (2007) 0.94
Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue. Mol Pharm (2013) 0.92
Polymyxin B enhances ISS-mediated immune responses across multiple species. Cell Immunol (2004) 0.91
Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles. Cell Immunol (2003) 0.90
Tumor cell killing enabled by listeriolysin O-liposome-mediated delivery of the protein toxin gelonin. J Biol Chem (2003) 0.89
Chemical and enzymatic stability of amino acid prodrugs containing methoxy, ethoxy and propylene glycol linkers. Mol Pharm (2009) 0.88
Enhanced in vivo gene expression mediated by listeriolysin O incorporated anionic LPDII: Its utility in cytotoxic T lymphocyte-inducing DNA vaccine. J Control Release (2010) 0.86
Cytosolic delivery of viral nucleoprotein by listeriolysin O-liposome induces enhanced specific cytotoxic T lymphocyte response and protective immunity. Mol Pharm (2004) 0.86
A fluorescent hPept1 transporter substrate for uptake screening. Pharm Res (2003) 0.83
A minimal human immunostimulatory CpG motif that potently induces IFN-gamma and IFN-alpha production. Eur J Immunol (2003) 0.83
Encapsulating immunostimulatory CpG oligonucleotides in listeriolysin O-liposomes promotes a Th1-type response and CTL activity. Mol Pharm (2012) 0.81
Specificity of a prodrug-activating enzyme hVACVase: the leaving group effect. Mol Pharm (2010) 0.80
The achievement of mass balance by simultaneous quantification of floxuridine prodrug, floxuridine, 5-fluorouracil, 5-dihydrouracil, α-fluoro-β-ureidopropionate, α-fluoro-β-alanine using LC-MS. J Chromatogr B Analyt Technol Biomed Life Sci (2011) 0.79
Targeting and blocking B7 costimulatory molecules on antigen-presenting cells using CTLA4Ig-conjugated liposomes: in vitro characterization and in vivo factors affecting biodistribution. Pharm Res (2003) 0.79
Enhanced plasmid DNA delivery using anionic LPDII by listeriolysin O incorporation. J Gene Med (2005) 0.77
Cytomegalovirus protease targeted prodrug development. Mol Pharm (2013) 0.77
Mutants of listeriolysin O for enhanced liposomal delivery of macromolecules. J Biotechnol (2013) 0.77
Design and characterization of novel recombinant listeriolysin O-protamine fusion proteins for enhanced gene delivery. Mol Pharm (2015) 0.76
Puromycin-sensitive aminopeptidase: an antiviral prodrug activating enzyme. Antiviral Res (2009) 0.76
Intranasal immunization with influenza vaccine and a detoxified mutant of heat labile enterotoxin from Escherichia coli (LTK63). J Control Release (2002) 0.76
1656: MASSIVE LEFT VENTRICULAR ANEURYSM AFTER MYOCARDIAL INFARCTION. Crit Care Med (2016) 0.75
Proline prodrug of melphalan, prophalan-L, demonstrates high therapeutic index in a murine melanoma model. Eur J Pharm Biopharm (2007) 0.75
Absorbance-based assay for membrane disruption by antimicrobial peptides and synthetic copolymers using pyrroloquinoline quinone-loaded liposomes. Anal Biochem (2011) 0.75
Molecular pharmaceutics, a vision for the future. Mol Pharm (2005) 0.75
Visual detection of single-stranded target DNA using pyrroloquinoline-quinone-loaded liposomes as a tracer. Anal Biochem (2010) 0.75
Thoughts from the frontiers of science: the Gordon Research Conference on Drug Carriers in Medicine and Biology (August 20-25, 2006). Mol Pharm (2006) 0.75